{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-26.00","upperLimit":"47.50","value":"7.55"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"The percent change in dose is relative to the busulfan dose administered at the Baseline Visit (Day -12 to -9) when a dose of 0.8 mg/kg was administered and on Day -5 when the Seattle Cancer Care Alliance recommended PK-adjusted dose was administered.","dispersionType":"Full Range","groups":[{"description":"Intravenous (IV) busulfan was administered as a single daily 3-hour continuous infusion based on the PK-directed dose recommendation for 4 days beginning on Day -5 followed by a single bortezomib 1.3 mg/m\\^2 dose administered as a 3 to 5-second bolus IV injection on Day -1 prior to HSCT.","id":"OG000","title":"IV Busulfan"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat population included all participants who received the PK-directed IV busulfan followed by autologous HSCT.","reportingStatus":"POSTED","timeFrame":"Baseline (Day -12 to -9), Day -5","title":"Percent Change in IV Busulfan Dose","type":"SECONDARY","unitOfMeasure":"Percent change"}